Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.

Bernadette A M Heemskerk-Gerritsen,Antoinette Hollestelle,Christi J van Asperen,Irma van den Beek,Willemien J van Driel,Klaartje van Engelen,Encarna B Gómez Garcia,Joanne A de Hullu,Marco J Koudijs,Marian J E Mourits,Maartje J Hooning,Ingrid A Boere

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER（2022）

引用 1|浏览0

暂无评分

摘要

For epithelial ovarian cancer patients who received chemotherapy, we confirmed survival benefit for BRCA1 and BRCA2 germline pathogenic variant carriers. This may indicate higher sensitivity to chemotherapy, both in first line treatment and in the recurrent setting. The observed benefit appears to be limited to a relatively short period after epithelial ovarian cancer diagnosis.

查看译文

关键词

epithelial ovarian cancer,ovarian cancer,overall survival,progression-free

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要